Fig. 5 | Leukemia

Fig. 5

From: Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies

Fig. 5

Frequency of iC9-CD19.ζ-MC-modified T cells and cytokine production can be modulated by titration of rimiducid. a NSG mice were engrafted with non-modified CD19+ Raji tumor cells and subsequently treated with 5 × 106 T cells transduced with iC9-CD19.ζ-MC and EGFPluc retroviral vectors on day 7 post-tumor injection. CAR-T cell levels were assessed by BLI before and 24 and 48 h after i.p. injection of rimiducid (0.00005, 0.0005, 0.005, 0.05, 0.5, and 5 mg/kg). b CAR-T cell BLI and c serum cytokine levels of IFN-γ, IL-6, IL-13, and TNF-a at 24 h post-rimiducid treatment were measured. **, ***, and **** represent a P-value of <0.01, 0.005, and 0.001, respectively

Back to article page